After a triple-negative breast cancer patient progresses on a first-line TROP2 antibody-drug conjugate (ADC), experts advise against immediately sequencing another ADC. Due to suspected cross-resistance, the recommended strategy is to return to traditional chemotherapy agents like taxanes or carboplatin, which remain effective options, before considering another ADC in later lines.

An expert would not offer just the adjuvant portion of the EV-Pembro regimen to a patient who went straight to surgery, even though the full perioperative (neoadjuvant + adjuvant) regimen is approved. This highlights a strict adherence to trial data, where the lack of specific evidence for a purely adjuvant application prevents off-label use.

With only one-third of pancreatic cancer patients advancing to second-line treatment, oncologists must carefully select first-line therapies. This may involve choosing less toxic combinations to preserve patient fitness for subsequent treatments, like emerging KRAS inhibitors, rather than using the most aggressive option upfront.

Beyond improving survival in metastatic disease, clinicians leverage liposomal irinotecan's high tumor shrinkage rate to make borderline resectable or locally advanced pancreatic cancer patients eligible for curative surgery. This strategic use aims to increase the small percentage of patients who can achieve a cure.

Subgroup analyses of menin inhibitor trials reveal a key difference for treatment sequencing. Patients with prior venetoclax exposure showed lower response rates to Revumenitib. In contrast, early data for Ziftomenib suggests prior venetoclax use did not negatively impact its efficacy.

In metastatic breast cancer, approximately one-third of patients are unable to proceed to a second line of therapy due to disease progression or declining performance status. This high attrition rate argues for using the most effective agents, such as ADCs, in the first-line setting.

In ROS1-positive NSCLC, starting with older TKIs before newer agents like Repotrectinib dramatically worsens outcomes. Median overall survival has not been reached after 5 years for TKI-naive patients but drops to just 25 months for those pre-treated with another TKI. This starkly quantifies the critical importance of using the most effective treatment first.

New targeted therapies are often approved only for first-line use. This forces clinicians into a difficult choice: using one effective drug like a checkpoint inhibitor means forfeiting the chance to use another, like zolbetuximab, in a subsequent line of treatment, thereby losing a valuable therapeutic option.

Despite a study showing a minor hazard ratio benefit for a FLOT-like regimen over FOLFOX in the metastatic setting, experts advise against it. The significant increase in toxicity outweighs the small efficacy advantage, especially in symptomatic metastatic patients who are often nutritionally deficient and less able to tolerate aggressive chemotherapy.